It was found that Gleevec could improve the overall survival rate of CML patients

Jin Jing, a researcher from Howard Hughes Medical Research Institute in the United States, found through 11 years of follow-up research that Gleevec can make the overall survival rate of CML patients reach 83.3% The research is published in the International Journal New England Journal of medicine The study recruited 1106 CML patients from 177 cancer research centers in more than 16 countries around the world; the long-term success of the treatment also confirmed the gratifying results observed in the first clinical trials conducted with Gleevec (http:// The discovery of Gleevec ushered in a new era of individualized cancer therapy for scientists, and also helped researchers turn off the functions of cells that can promote cancer without damaging healthy cells (http:// It was found that Gleevec not only can treat CML patients, but also can effectively treat various types of cancer, such as CML in children and gastrointestinal stromal tumor (GIST) A recent study in the journal JAMA oncology found that nearly a quarter of patients with GIST treated with Gleevec had a life span of more than 10 years Dr Michael Heinrich, researcher, said that 15 years before the development of Gleevec, patients with malignant gists often faced a survival period of only 18 months Now, under the treatment of Gleevec, some patients' life expectancy has even increased by more than 10 years One of the great advantages of using Gleevec to treat CML patients, Druker said, is that many patients will be diagnosed and treated when the disease is chronic The results of this study show that the role of Gleevec in the effective treatment of CML patients can motivate researchers to develop more effective individualized cancer therapy, of course, researchers also need to diagnose and treat patients as early as possible in the early stage of disease.